Edition:
United States

Neurocrine Biosciences Inc (NBIX.OQ)

NBIX.OQ on NASDAQ Stock Exchange Global Select Market

58.83USD
4:00pm EDT
Change (% chg)

$2.03 (+3.57%)
Prev Close
$56.80
Open
$57.50
Day's High
$59.25
Day's Low
$57.50
Volume
420,931
Avg. Vol
367,104
52-wk High
$60.00
52-wk Low
$37.37

Chart for

About

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-re... (more)

Overall

Beta: 0.41
Market Cap(Mil.): $5,010.99
Shares Outstanding(Mil.): 88.22
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Perceptive Advisors reports 5.3 pct passive stake in Neurocrine Biosciences

* Perceptive Advisors LLC reports 5.3 percent passive stake in Neurocrine Biosciences Inc as of September 6, 2017 - SEC filing‍​ Source: (http://bit.ly/2wOUVQY) Further company coverage:

Sep 08 2017

BRIEF-Neurocrine Biosciences Q2 loss per share $0.68

* Q2 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S

Aug 03 2017

BRIEF-Neurocrine Biosciences says PDUFA goal date is Oct. 14 for Ingrezza 80 mg capsules

* Neurocrine Biosciences Inc - has been advised that PDUFA goal date is october 14, 2017 for Ingrezza 80 mg capsules - sec filing Source text for Eikon: (http://bit.ly/2spiVra) Further company coverage:

Jul 05 2017

BRIEF-Neurocrine Bio's Ingrezza fails study in pedriatric Tourette's patients

* Neurocrine announces phase ii results of vmat2 inhibitor ingrezza® for treatment of tourette syndrome

May 23 2017

BRIEF-Neurocrine Biosciences reports Q1 loss per share $0.90

* Q1 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S

May 09 2017

BRIEF-Neurocrine Biosciences prices $450 mln convertible senior notes offering

* Priced offering of $450.0 million aggregate principal amount of 2.25% convertible senior notes due 2024 Source text for Eikon: Further company coverage:

Apr 26 2017

Neurocrine Biosciences gets FDA's OK for movement disorder drug

The U.S. Food and Drug Administration approved Neurocrine Biosciences Inc's drug to treat tardive dyskinesia, a side effect of antipsychotic medications characterized by uncontrolled movements of the face and body, the company said.

Apr 11 2017

UPDATE 1-Neurocrine Biosciences gets FDA's OK for movement disorder drug

April 11 The U.S. Food and Drug Administration approved Neurocrine Biosciences Inc's drug to treat tardive dyskinesia, a side effect of antipsychotic medications characterized by uncontrolled movements of the face and body, the company said.

Apr 11 2017

Neurocrine Biosciences gets FDA OK for movement disorder drug

April 11 The U.S. Food and Drug Administration on Tuesday approved Neurocrine Biosciences Inc's drug to treat tardive dyskinesia, a side effect of antipsychotic medications characterized by uncontrolled movement of the face and body, the company said. The drug, Ingrezza, is the first treatment to be approved for the irreversible disorder, which occurs in 5 percent to 8 percent of patients taking antipsychotic drugs. Ingrezza is the company's first commercial product.

Apr 11 2017

BRIEF-Neurocrine announces FDA approval of Ingrezza TM (valbenazine) capsules

* Neurocrine announces FDA approval of Ingrezza TM (valbenazine) capsules as the first and only approved treatment for adults with tardive dyskinesia (TD)

Apr 11 2017

Earnings vs. Estimates